E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival. This study seeks to determine 1) if E7 TCR-T cells can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, and 3) the disease-free survival rate at 2 and 5 years. Participants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up to assess safety and determine tumor response and will return to their primary oncology team for definitive therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie (potwierdzeniem mikroskopowym) raka pierwotnego z zaawansowanym stadium
- •Nowotwór zawierający wirus HPV typ 16 potwierdzoną specjalistycznym testowaniem
- •Posiadanie czynnika genetycznego HLA-A*02:01 (genetyczny marker krwi)
- •Wiek co najmniej 18 lat
- •Dostateczne funkcje narządów (wątroba, nerki, szpik kostny) potwierdzone badaniami krwi
- •Test ujemny na HIV, wirusowe zapalenie wątroby B i C
- •Dla kobiet zdolnych do zajścia w ciążę: zgoda na stosowanie antykoncepcji przez 4 miesiące
- •Mierzalne zmiany nowotworowe widoczne w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Rutgers Cancer Institute
New Brunswick, United States
RWJBarnabas Health - Robert Wood Johnson University Hospital
New Brunswick, United States
Trial contact
Tobi Adewale
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.